BACKGROUND: For early phase trials of novel interventions-such as gene transfer for Parkinson disease (PD)--whose focus is primarily on safety and tolerability, it is important that participants have a realistic understanding of the goals of such research. Recently, some have expressed concern that patients with PD may have unrealistic expectations. METHODS: The authors examined why patients with PD might volunteer for invasive early phase research by interviewing 92 patients with PD and comparing those who would (n = 46) and those who would not (n = 46) participate in a hypothetical phase I gene-transfer study. RESULTS: The two groups' demographic, clinical, functional, and quality of life measures, as well as their understanding of the research protocol, were similar. The groups did not differ on their perception of potential for personal benefit nor on the level of likelihood of benefit they saw as a precondition for volunteering. However, those willing to participate tended to perceive lower probability of risk, were tolerant of greater probability of risk, and were more optimistic about the phase I study's potential benefits to society. They also appeared more decisive and action-oriented than the unwilling group. CONCLUSIONS: It is likely that the decision whether to participate in early phase PD gene transfer studies will depend mostly on patients' attitudes regarding risk, optimism about science, and an action orientation, rather than on their clinical, functional, or demographic characteristics.
BACKGROUND: For early phase trials of novel interventions-such as gene transfer for Parkinson disease (PD)--whose focus is primarily on safety and tolerability, it is important that participants have a realistic understanding of the goals of such research. Recently, some have expressed concern that patients with PD may have unrealistic expectations. METHODS: The authors examined why patients with PD might volunteer for invasive early phase research by interviewing 92 patients with PD and comparing those who would (n = 46) and those who would not (n = 46) participate in a hypothetical phase I gene-transfer study. RESULTS: The two groups' demographic, clinical, functional, and quality of life measures, as well as their understanding of the research protocol, were similar. The groups did not differ on their perception of potential for personal benefit nor on the level of likelihood of benefit they saw as a precondition for volunteering. However, those willing to participate tended to perceive lower probability of risk, were tolerant of greater probability of risk, and were more optimistic about the phase I study's potential benefits to society. They also appeared more decisive and action-oriented than the unwilling group. CONCLUSIONS: It is likely that the decision whether to participate in early phase PD gene transfer studies will depend mostly on patients' attitudes regarding risk, optimism about science, and an action orientation, rather than on their clinical, functional, or demographic characteristics.
Authors: Scott Y H Kim; Renee M Wilson; H Myra Kim; Robert G Holloway; Raymond G De Vries; Samuel A Frank; Karl Kieburtz Journal: Mov Disord Date: 2012-02-07 Impact factor: 10.338
Authors: Scott Y H Kim; Lauren Schrock; Renee M Wilson; Samuel A Frank; Robert G Holloway; Karl Kieburtz; Raymond G de Vries Journal: IRB Date: 2009 Sep-Oct
Authors: Rebecca D Pentz; Margaret White; R Donald Harvey; Zachary Luke Farmer; Yuan Liu; Colleen Lewis; Olga Dashevskaya; Taofeek Owonikoko; Fadlo R Khuri Journal: Cancer Date: 2012-01-31 Impact factor: 6.860
Authors: Jonathan Kimmelman; Alex John London; Bernard Ravina; Tim Ramsay; Mark Bernstein; Alan Fine; Frank W Stahnisch; Marina Elena Emborg Journal: Mov Disord Date: 2009-10-15 Impact factor: 10.338